MX2022006490A - Uso de inhibidores de sglt-2 en el secado de mamiferos no humanos. - Google Patents
Uso de inhibidores de sglt-2 en el secado de mamiferos no humanos.Info
- Publication number
- MX2022006490A MX2022006490A MX2022006490A MX2022006490A MX2022006490A MX 2022006490 A MX2022006490 A MX 2022006490A MX 2022006490 A MX2022006490 A MX 2022006490A MX 2022006490 A MX2022006490 A MX 2022006490A MX 2022006490 A MX2022006490 A MX 2022006490A
- Authority
- MX
- Mexico
- Prior art keywords
- sglt
- drying
- inhibitors
- human mammals
- human mammal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/116—Heterocyclic compounds
- A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/24—Compounds of alkaline earth metals, e.g. magnesium
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Birds (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere al uso de al menos un inhibidor de SGLT-2 en un mamífero no humano, preferentemente rumiante, preferentemente para el secado de un mamífero no humano, preferentemente rumiante, así como métodos correspondientes, tales como mejorar y/o facilitar el secado de un mamífero no humano, preferentemente rumiante, que comprende administrar a tal mamífero no humano, preferentemente rumiante, al menos un inhibidor de SGLT-2.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19212134 | 2019-11-28 | ||
EP20200103 | 2020-10-05 | ||
PCT/EP2020/083267 WO2021105152A1 (en) | 2019-11-28 | 2020-11-25 | Use of sglt-2 inhibitors in the drying-off of non-human mammals |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022006490A true MX2022006490A (es) | 2022-07-04 |
Family
ID=73543293
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022006490A MX2022006490A (es) | 2019-11-28 | 2020-11-25 | Uso de inhibidores de sglt-2 en el secado de mamiferos no humanos. |
Country Status (12)
Country | Link |
---|---|
US (2) | US11759474B2 (es) |
EP (1) | EP4064854A1 (es) |
JP (2) | JP7441946B2 (es) |
KR (1) | KR20220109431A (es) |
CN (1) | CN114727624A (es) |
AU (1) | AU2020394498A1 (es) |
BR (1) | BR112022010385A2 (es) |
CA (1) | CA3158368A1 (es) |
CL (1) | CL2022001368A1 (es) |
MX (1) | MX2022006490A (es) |
UY (1) | UY38969A (es) |
WO (1) | WO2021105152A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10966921B2 (en) | 2018-05-23 | 2021-04-06 | Boehringer Ingelheim Vetmedica Gmbh | Use of an oral bolus in the drying-off of dairy cattle |
EP4376819A1 (en) | 2021-07-28 | 2024-06-05 | Boehringer Ingelheim Vetmedica GmbH | Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals |
WO2023227492A1 (en) | 2022-05-25 | 2023-11-30 | Boehringer Ingelheim Vetmedica Gmbh | Aqueous pharmaceutical compositions comprising sglt-2 inhibitors |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4412993A (en) | 1980-01-25 | 1983-11-01 | The Upjohn Company | Method of treating pseudopregnancy, galactorrhea and mastitis in mammals |
RU2232767C2 (ru) | 1999-08-31 | 2004-07-20 | Киссеи Фармасьютикал Ко., Лтд. | Глюкопиранозилоксипиразольные производные, фармацевтические композиции, содержащие эти производные, и промежуточные соединения для их получения |
PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
US6515117B2 (en) | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
US6391849B1 (en) | 1999-11-19 | 2002-05-21 | Agricultural Research Organization, The Volcani Center | Method and pharmaceutical composition for disrupting lactation in a mammary gland and for treating and preventing mastitis |
AU2002223127A1 (en) | 2000-11-30 | 2002-06-11 | Kissei Pharmaceutical Co., Ltd. Intellectual Property | Glucopyranosyloxybenzyl benzene derivatives, medicinal compositions containing the same and intermediates in the production thereof |
SI1354888T1 (sl) | 2000-12-28 | 2009-10-31 | Kissei Pharmaceutical | Glukopiranoziloksipirazolni derivati in njihova uporaba v zdravilih |
EP1489089A4 (en) | 2002-03-22 | 2009-10-28 | Kissei Pharmaceutical | CRYSTALS OF GLUCOPYRANOSYLOXYBENZYLBENZEN DERIVATE |
DE10231370B4 (de) | 2002-07-11 | 2006-04-06 | Sanofi-Aventis Deutschland Gmbh | Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
TWI310033B (en) | 2003-03-14 | 2009-05-21 | Yamanouchi Pharma Co Ltd | C-glycoside derivatives or salts thereof |
US20040258778A1 (en) | 2003-03-31 | 2004-12-23 | Farmar Jill B. | Lactation cessation and breast engorgement compositions and method of use |
GB0313892D0 (en) | 2003-06-16 | 2003-07-23 | Hannah Res Inst | Control of lactation |
SI1651658T2 (sl) | 2003-08-01 | 2020-12-31 | Mitsubishi Tanabe Pharma Corporation | Nove spojine, ki imajo inhibitorno aktivnost proti transporterju, ki je odvisen od natrija |
US20050191653A1 (en) * | 2003-11-03 | 2005-09-01 | Freier Susan M. | Modulation of SGLT2 expression |
SG151271A1 (en) | 2004-03-16 | 2009-04-30 | Boehringer Ingelheim Int | Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof |
AR051446A1 (es) | 2004-09-23 | 2007-01-17 | Bristol Myers Squibb Co | Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2) |
EP1828216B1 (en) | 2004-12-16 | 2008-09-10 | Boehringer Ingelheim International GmbH | Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
UA91546C2 (uk) | 2005-05-03 | 2010-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ |
US7723309B2 (en) | 2005-05-03 | 2010-05-25 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
DE602006017566D1 (de) | 2005-08-30 | 2010-11-25 | Boehringer Ingelheim Pharma | Glucopyranosyl-substituierte benzyl-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür |
JP5345846B2 (ja) | 2005-09-08 | 2013-11-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 1−クロロ−4−(β−D−グルコピラノス−1−イル)−2−(4−エチニル−ベンジル)−ベンゼンの結晶形態、その製造方法及び薬剤製造のためのそれらの使用 |
AR056195A1 (es) | 2005-09-15 | 2007-09-26 | Boehringer Ingelheim Int | Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos |
EP1989191B1 (en) | 2006-02-15 | 2011-07-20 | Boehringer Ingelheim International GmbH | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture |
TWI370818B (en) | 2006-04-05 | 2012-08-21 | Astellas Pharma Inc | Cocrystal of c-glycoside derivative and l-proline |
PE20080697A1 (es) | 2006-05-03 | 2008-08-05 | Boehringer Ingelheim Int | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
EP2019679B1 (en) | 2006-05-23 | 2018-06-20 | Theracos, Inc. | Glucose transport inhibitors and methods of use |
US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
TWI403516B (zh) | 2006-07-27 | 2013-08-01 | Chugai Pharmaceutical Co Ltd | To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes |
TWI499414B (zh) | 2006-09-29 | 2015-09-11 | Lexicon Pharmaceuticals Inc | 鈉與葡萄糖第2型共同運輸體(co-transporter 2)的抑制物與其應用方法 |
EP2086991A1 (en) | 2006-10-27 | 2009-08-12 | Boehringer Ingelheim International GmbH | CRYSTALLINE FORM OF 4-(ß-D-GLUCOPYRANOS-1-YL)-1-METHYL-2-[4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYL]-BENZENE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS |
EP2079753A1 (en) | 2006-11-06 | 2009-07-22 | Boehringer Ingelheim International GmbH | Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture |
NZ598778A (en) | 2006-11-09 | 2013-09-27 | Boehringer Ingelheim Int | Combination therapy with SGLT-2 inhibitors and their pharmaceutical compositions |
UY30730A1 (es) | 2006-12-04 | 2008-07-03 | Mitsubishi Tanabe Pharma Corp | Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno |
AR065809A1 (es) | 2007-03-22 | 2009-07-01 | Bristol Myers Squibb Co | Formulaciones farmaceuticas que contienen un inhibidor sglt2 |
TW200904454A (en) * | 2007-03-22 | 2009-02-01 | Bristol Myers Squibb Co | Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof |
CA2694029C (en) | 2007-07-26 | 2016-10-04 | Lexicon Pharmaceuticals, Inc. | Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors |
FR2920045B1 (fr) | 2007-08-16 | 2010-03-12 | Valeo Systemes Thermiques | Evaporateur a nappes multiples, en particulier pour un circuit de climatisation de vehicule automobile |
PE20090597A1 (es) | 2007-08-16 | 2009-06-06 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de pirazol-o-glucosido |
UA105480C2 (uk) | 2007-09-10 | 2014-05-26 | Янссен Фармацевтика Н.В. | Спосіб одержання сполук, які застосовують як інгібітори натрійзалежного переносника глюкози |
MX2010012656A (es) * | 2008-05-22 | 2010-12-20 | Squibb Bristol Myers Co | Metodo para tratar la hiperuricemia empleando un inhibidor de sglt2 y composicion que contiene el mismo. |
PE20110288A1 (es) | 2008-08-28 | 2011-05-26 | Pfizer | Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol |
FR2936710B1 (fr) | 2008-10-07 | 2011-01-07 | Ceva Sante Animale | Composition veterinaire antiprolactinique destinee aux ruminants |
US8133916B1 (en) | 2009-03-10 | 2012-03-13 | Amelgo, LLC | Control of milk production and mammary involution |
KR101811997B1 (ko) | 2009-09-30 | 2017-12-26 | 베링거 인겔하임 인터내셔날 게엠베하 | 1클로로4(베타d글루코피라노스1일)2(4((s)테트라하이드로푸란3일옥시)벤질)벤젠의 결정형의 제조방법 |
IN2012DN02751A (es) | 2009-09-30 | 2015-09-18 | Boehringer Ingelheim Int | |
FR2971423B1 (fr) | 2011-02-15 | 2014-01-10 | Ceva Sante Animale | Composition veterinaire antiprolactinique destinee aux ruminants |
ES2759980T3 (es) | 2012-03-19 | 2020-05-12 | Mileutis Ltd | Péptidos para el manejo de la lactación |
US9145434B2 (en) | 2012-07-26 | 2015-09-29 | Boehringer Ingelheim International Gmbh | Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments |
JP2017515908A (ja) * | 2014-05-16 | 2017-06-15 | アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag | Sglt2インヒビター誘発性グルカゴン分泌の抑制方法 |
JP6027710B1 (ja) * | 2014-12-25 | 2016-11-16 | 田辺三菱製薬株式会社 | 糖尿病治療用固形製剤 |
WO2016134486A1 (en) * | 2015-02-27 | 2016-09-01 | Steinberg Gregory | Use of canagliflozin and derivatives thereof in the treatment of cancer |
AU2016310535B2 (en) | 2015-08-27 | 2021-08-19 | Boehringer Ingelheim Vetmedica Gmbh | Liquid pharmaceutical compositions comprising SGLT-2 inhibitors |
CN109310705A (zh) | 2016-03-18 | 2019-02-05 | 加拿大农业及农业食品部 | 干奶时加速乳腺退化和预防乳腺感染的方法 |
WO2019051540A1 (en) * | 2017-09-12 | 2019-03-21 | Garvan Institute Of Medical Research | METHODS OF REDUCING OR STOPPING LACTATION IN NON-HUMAN MAMMALS AND RELATED REACTIVES |
EA202091466A1 (ru) | 2017-12-19 | 2020-10-23 | Бёрингер Ингельхайм Ветмедика Гмбх | Синтез сокристалла 1:1:1 1-циано-2-(4-циклопропилбензил)-4-(-d-глюкопираноз-1-ил)бензола, l-пролина и воды |
-
2020
- 2020-11-25 BR BR112022010385A patent/BR112022010385A2/pt unknown
- 2020-11-25 CA CA3158368A patent/CA3158368A1/en active Pending
- 2020-11-25 AU AU2020394498A patent/AU2020394498A1/en active Pending
- 2020-11-25 US US17/104,414 patent/US11759474B2/en active Active
- 2020-11-25 KR KR1020227022056A patent/KR20220109431A/ko unknown
- 2020-11-25 JP JP2022529396A patent/JP7441946B2/ja active Active
- 2020-11-25 WO PCT/EP2020/083267 patent/WO2021105152A1/en unknown
- 2020-11-25 CN CN202080081166.4A patent/CN114727624A/zh active Pending
- 2020-11-25 MX MX2022006490A patent/MX2022006490A/es unknown
- 2020-11-25 UY UY0001038969A patent/UY38969A/es unknown
- 2020-11-25 EP EP20811328.2A patent/EP4064854A1/en active Pending
-
2022
- 2022-05-25 CL CL2022001368A patent/CL2022001368A1/es unknown
-
2023
- 2023-07-05 US US18/346,935 patent/US20230338406A1/en active Pending
-
2024
- 2024-02-19 JP JP2024022820A patent/JP2024059741A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112022010385A2 (pt) | 2022-08-23 |
EP4064854A1 (en) | 2022-10-05 |
WO2021105152A1 (en) | 2021-06-03 |
US20230338406A1 (en) | 2023-10-26 |
UY38969A (es) | 2021-05-31 |
US11759474B2 (en) | 2023-09-19 |
CL2022001368A1 (es) | 2023-02-24 |
AU2020394498A1 (en) | 2022-06-09 |
CN114727624A (zh) | 2022-07-08 |
JP2024059741A (ja) | 2024-05-01 |
KR20220109431A (ko) | 2022-08-04 |
JP7441946B2 (ja) | 2024-03-01 |
US20210161930A1 (en) | 2021-06-03 |
JP2023503437A (ja) | 2023-01-30 |
CA3158368A1 (en) | 2021-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022006490A (es) | Uso de inhibidores de sglt-2 en el secado de mamiferos no humanos. | |
CR20220070A (es) | Inhibidores de parp1 | |
CR20220351A (es) | Inhibidores de proteínas kras mutantes | |
EP4218804A3 (en) | Use of myostatin inhibitors and combination therapies | |
ZA202208792B (en) | Methods of treating and preventing graft versus host disease | |
PH12020551881A1 (en) | Mcl-1 inhibitors | |
MX2022007472A (es) | Uso de plinabulina en combinacion con inhibidores de punto de control inmunitario. | |
WO2017059319A3 (en) | Combination therapy of bromodomain inhibitors and checkpoint blockade | |
PH12016501668A1 (en) | Compositions and methods for the reduction or prevention of hepatic steatosis | |
MX2020006115A (es) | Inhibidores de la vía de respuesta al estrés integrada. | |
PE20170140A1 (es) | Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer | |
MX2021015210A (es) | Inhibidores de la via de respuesta al estres integrada. | |
NO20082907L (no) | Fremgangsmate for anvendelse av IL6 antagonister med proteasom-inhibitorer | |
PH12019550249A1 (en) | Solid compositions for oral administration | |
MX2020013269A (es) | Inhibidores de la vía de respuesta al estrés integrada. | |
EA200800755A1 (ru) | Ikk ингибиторы, предназначенные для лечения эндометриоза | |
PH12021551282A1 (en) | Radioimmunoconjugates and checkpoint inhibitor combination therapy | |
MX2021010545A (es) | Inhibidores de la vía de cinasa janus 1 (jak1) para el tratamiento de la disfunción crónica del aloinjerto pulmonar. | |
PH12017501980A1 (en) | The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc) | |
MX2021006347A (es) | Metodos de tratamiento de cánceres que sobreexpresan whsc1 mediante la inhibición de setd2. | |
EA202191631A1 (ru) | Композиции, содержащие бактериальные штаммы | |
WO2019204332A3 (en) | Pak4 inhibitors and methods of use | |
MX2020012782A (es) | Inhibidor de ccr5 para el uso en el tratamiento de cancer. | |
MX2021006915A (es) | Inhibidores de cxcr7 para el tratamiento de cancer. | |
WO2020055906A8 (en) | Methods of treating cancer by inhibiting ubiquitin conjugating enzyme e2 k (ube2k) |